0	6	Immune	immune	JJ
7	16	functions	function	NNS
16	17	,	,	,
18	26	clinical	clinical	JJ
27	37	parameters	parameter	NNS
38	41	and	and	CC
42	49	hormone	hormone	NN
50	58	receptor	receptor	NN
59	65	status	status	NN
66	68	in	in	IN
69	75	breast	breast	NN
76	82	cancer	cancer	NN
83	91	patients	patient	NNS
91	92	.	.	.

94	96	We	we	PRP
97	101	have	have	VBP
102	109	carried	carry	VBN
110	113	out	out	RP
114	115	a	a	DT
116	124	detailed	detailed	JJ
125	133	analysis	analysis	NN
134	136	of	of	IN
137	140	the	the	DT
141	149	cellular	cellular	JJ
150	156	immune	immune	JJ
157	166	functions	function	NNS
167	169	of	of	IN
170	176	breast	breast	NN
177	183	cancer	cancer	NN
184	192	patients	patient	NNS
193	195	in	in	IN
196	206	comparison	comparison	NN
207	211	with	with	IN
212	219	healthy	healthy	JJ
220	228	controls	control	NNS
228	229	.	.	.

230	231	A	a	DT
232	240	possible	possible	JJ
241	252	correlation	correlation	NN
253	260	between	between	IN
261	267	immune	immune	JJ
268	271	and	and	CC
272	280	clinical	clinical	JJ
281	291	parameters	parameter	NNS
292	295	was	be	VBD
296	304	analysed	analyse	VBN
305	307	in	in	IN
308	310	50	50	CD
311	317	breast	breast	NN
318	324	cancer	cancer	NN
325	333	patients	patient	NNS
333	334	.	.	.

335	341	Immune	immune	JJ
342	352	parameters	parameter	NNS
352	353	,	,	,
354	361	natural	natural	JJ
362	368	killer	killer	NN
369	373	cell	cell	NN
374	377	and	and	CC
378	379	T	t	NN
380	390	lymphocyte	lymphocyte	NN
391	400	functions	function	NNS
401	404	and	and	CC
405	408	the	the	DT
409	416	numbers	number	NNS
417	419	of	of	IN
420	431	circulating	circulate	VBG
432	433	T	t	NN
434	445	lymphocytes	lymphocyte	NNS
446	450	were	be	VBD
451	459	analysed	analyse	VBN
460	467	against	against	IN
468	471	the	the	DT
472	480	clinical	clinical	JJ
481	491	parameters	parameter	NNS
492	502	comprising	comprise	VBG
503	506	the	the	DT
507	513	tumour	tumour	NN
514	520	burden	burden	NN
520	521	,	,	,
522	525	the	the	DT
526	531	stage	stage	NN
532	534	of	of	IN
535	538	the	the	DT
539	546	disease	disease	NN
547	550	and	and	CC
551	554	the	the	DT
555	565	expression	expression	NN
566	568	of	of	IN
569	576	hormone	hormone	NN
577	586	receptors	receptor	NNS
587	589	on	on	IN
590	593	the	the	DT
594	600	tumour	tumour	NN
600	601	.	.	.

602	604	In	in	IN
605	610	order	order	NN
611	613	to	to	TO
614	621	analyse	analyse	VB
622	625	the	the	DT
626	632	immune	immune	JJ
633	641	function	function	NN
642	646	data	datum	NNS
647	658	effectively	effectively	RB
658	659	,	,	,
660	663	low	low	JJ
664	674	responders	responder	NNS
675	679	were	be	VBD
680	690	identified	identify	VBN
691	695	with	with	IN
696	705	stringent	stringent	JJ
706	713	cut-off	cut-off	JJ
714	720	values	value	NNS
720	721	.	.	.

722	734	Considerably	considerably	RB
735	741	higher	high	JJR
742	753	proportions	proportion	NNS
754	756	of	of	IN
757	760	low	low	JJ
761	771	responders	responder	NNS
772	776	were	be	VBD
777	782	found	find	VBN
783	788	among	among	IN
789	792	the	the	DT
793	800	patient	patient	NN
801	811	population	population	NN
811	812	.	.	.

813	821	Elevated	elevated	JJ
822	829	numbers	number	NNS
830	832	of	of	IN
833	844	circulating	circulate	VBG
845	846	T	t	NN
847	858	lymphocytes	lymphocyte	NNS
859	862	and	and	CC
863	875	CD3-directed	cd3-directed	JJ
876	885	cytolysis	cytolysis	NN
886	896	correlated	correlate	VBD
897	901	with	with	IN
902	905	the	the	DT
906	916	expression	expression	NN
917	919	of	of	IN
920	929	oestrogen	oestrogen	NN
930	939	receptors	receptor	NNS
940	953	independently	independently	RB
954	956	of	of	IN
957	960	the	the	DT
961	982	clinical/histological	clinical/histological	JJ
983	993	parameters	parameter	NNS
993	994	.	.	.